Vaccinex, Inc. Appoints Chrystyna Bedrij Stecyk as Director and to its Compensation Committee
May 18, 2020 at 08:02 am EDT
Share
On May 14, 2020, the Board of Directors of Vaccinex, Inc. appointed Chrystyna Bedrij Stecyk as a director of the Company to fill a vacancy for a term expiring in 2022. The Board also appointed Ms. Stecyk to its Compensation Committee. There was not, and is not, any arrangement or understanding between Ms. Stecyk and any other person pursuant to which she was elected as a director.
Vaccinex, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including neurodegenerative diseases, cancer, and autoimmune disorders. Its lead product candidate, pepinemab, is in clinical development for the treatment of Alzheimerâs disease, head and neck, pancreatic and breast cancer. Its lead platform technologies include SEMA4D antibody platform and ActivMAb antibody discovery platform. SEMA4D antibody platform is the application of its knowledge of SEMA4D biology to develop pepinemab for the treatment of various diseases and conditions, including cancer. ActivMAb antibody discovery platform is a human antibody discovery platform based on a method for expressing multipass membrane proteins, as well as large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface of mammalian pox viruses.